Life sciences firm NanoVision Diagnostics, spun out from the University of Pittsburgh last year, raises $1.5m for early stage cancer detection.
NanoVision Diagnostics, a life sciences spin-out from the University of Pittsburgh, has raised $1.5m towards a planned £3.25m round, according to a SEC filing.
The Pittsburgh-based firm, which spun out from the university last year, is developing a diagnostics system for identifying early-stage cancer. NanoVision uses what it describes as optical biomarkers to detect cancer, which the firm says can lead to earlier detection, lower costs, and better outcomes. Currently, the firm is looking to detect cancers of the bile duct, pancreas, colon, cervix, bladder, and esophagus, but with an initial focus on breast cancer.
Michael Lang, chief executive and founder, told news provider Pittsburgh Business Times that the initial funding will be used to conduct more extensive clinical trials. Land did not disclose the sources of the investment.
